Nausea, Vomiting And Quality Of Life Of Patients With Cancer Undergoing Antineoplastic Treatment: An Evaluation By Pharmacists

Objective: This study aims to evaluate the frequency and severity of nausea and vomiting using two different instruments and relate them to quality of life (QOL) in patients with cancer receiving antineoplastic treatment. Methods: Severity of chemotherapy-induced nausea and vomiting (CINV) was measured by Common Terminology Criteria for Adverse Events (CTCAE) and a numerical scale. QOL was assessed using the Functional Assessment of Cancer Therapy-General questionnaire. Key findings: Of the 50 patients studied, 60.0% reported nausea (40.0% CTCAE grade 1; 66.7% moderate intensity on numerical scale) and 30.0% reported vomiting (46.7% CTCAE grades 1 and 2, each; 66.7% moderate intensity on numerical scale). CINV did not influence overall QOL. Conclusion: The frequency of CINV was high. There was no association between nausea/vomiting and overall QOL

Tuberculosis Outbreak in a Primary School, Milan, Italy

Investigation of an outbreak of tuberculosis (TB) in a primary school in Milan, Italy, found 15 schoolchildren had active TB disease and 173 had latent TB infection. TB was also identified in 2 homeless men near the school. Diagnostic delay, particularly in the index case-patient, contributed to the transmission of infection

Impact Of Drug Formulation And Free Platinum/cisplatin Ratio On Hypersensitivity Reactions To Cisplatin: Formulation Matters

What is known and objective Use of cisplatin can induce type I hypersensitivity reactions that may also be linked to the quality of the drug utilized. We observed cases of hypersensitivity that appeared to be associated with the brand of cisplatin used. The aim of this study was to compare two different brands of cisplatin in relation to type I hypersensitivity reactions. Methods Brand A was used in a tertiary care teaching hospital until 2012, and use of brand B started from January 2013, when the first hypersensitivity cases were observed. Patients were categorized based on symptom. Cisplatin of both brands was analysed by high-performance liquid chromatography (HPLC) and high-resolution electrospray ionization mass spectrometry (ESI-(+)-MS) and characterized according to US Pharmacopeia. Results and discussion There were no cases of hypersensitivity associated with the use of cisplatin brand A, whereas four of 127 outpatients that used cisplatin brand B were affected. The two brands were in accordance with the US Pharmacopeia parameters, and there was no significant difference in the total platinum levels between the two brands when analysed by HPLC. However, high-resolution ESI-(+)-MS analyses show that brand B contains approximately 2·7 times more hydrolysed cisplatin than brand A. What is new and conclusion The increase in the hydrolysed form of cisplatin found in brand B may be the cause of the hypersensitivity reaction observed in a subset of patients. We present the first study of the quality of drugs by high-resolution ESI-(+)-MS. Drug regulatory agencies and manufacturers should consider including measurement of hydrolysed cisplatin as a quality criterion for cisplatin formulations. Some cases of hypersensitivity that appeared to be associated with the brand of cisplatin used were observed. Increases in the hydrolyzed form of cisplatin found in brand B may be the cause of the hypersensitivity reaction observed in a subset of patients.4014147Rosenberg, B., Van Camp, L., Krigas, T., Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode (1965) Nature, 205, pp. 698-699Rosenberg, B., Van Camp, L., Trosko, J.E., Mansour, V.H., Platinum compounds: A new class of potent antitumour agents (1969) Nature, 222, pp. 385-386Reed, E., Cisplatin and its Analogs (2005) DeVita, Hellman and Rosenberg's Cancer: Principles & Practice of Oncology, p. 339. , De Vita V.T. Hellman S. Rosenberg S.A. eds. Philadelphia, PA: Lippincott Williams & WilkinsRabik, C.A., Dolan, M.E., Molecular mechanisms of resistance and toxicity associated with platinating agents (2007) Cancer Treat Rev, 33, pp. 9-23Weiss, R.B., Bruno, S., Hypersensitivity reactions to cancer chemotherapeutic agents (1981) Ann Int Med, 94, pp. 66-72Zweizig, S., Roman, L.D., Muderspach, L.I., Death from anaphylaxis to cisplatin: A case report (1994) Gynecol Oncol, 53, pp. 121-122Shlebak, A.A., Clark, P.I., Green, J.A., Hypersensitivity and cross-reactivity to cisplatin and analogues (1995) Cancer Chemother Pharmacol, 35, pp. 349-351Randall, J.M., Bharne, A.A., Bazhenova, L.A., Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer (2013) J Thorac Dis, 5, pp. E53-E57Sakaeda, T., Kadoyama, K., Yabuuchi, H., Niijima, S., Seki, K., Shiraishi, Y., Okuno, Y., Platinum agent-induced hypersensitivity reactions: Data mining of the public version of the FDA Event Reporting System, AERS (2011) Int J Med Sci, 8, pp. 332-338Görög, S., Drug safety, drug quality, drug analysis (2008) J Pharm Biomed Anal, 48, pp. 247-253Bannister, S.J., Sternson, L.A., Repta, A.J., Urine analysis of platinum Species derived from cis-D1-chlorodiammineplatinum(II) by high-performance liquid chromatography following derivatization with sodium diethyldithiocarbamate (1979) J Chromatogr, 173, pp. 333-342Lopes-Flores, A., Jurado, R., Garcia-Lopes, P., A high-performance liquid chromatographic assay for determination os cisplatin in plasma, cancer cell, and tumor samples (2005) J Pharmacol Toxicol Methods, 52, pp. 366-372USP, (2013) USP29- NF24. Water, Method, p. 521. , Rockville, MD: US Pharmacopeial ConventionHunter, D., Milton, R., Perry, K.M.A., Asthma caused by complex salts of platinum (1945) Br J Ind Med, 2, pp. 92-98Saunders, M.P., Denton, C.P., O'Brien, M.E.R., Blake, P., Gore, M., Wiltshaw, E., Hypersensitivity reactions to cisplatin and carboplatin - A report on six cases (1992) Ann Oncol, 3, pp. 574-576Vogel, W.H., Infusion reactions: Diagnosis, assessment, and management (2010) Clin J Oncol Nurs, 14, pp. E10-E21Lenz, H.J., Management and preparedness for infusion and hypersensitivity reactions (2007) Oncologist, 12, pp. 601-609Goldberg, A., Altaras, M.M., Mekori, Y.A., Beyth, Y., Confino-Cohen, R., Anaphylaxis to cisplatin: Diagnosis and value of pretreatment in prevention of recurrent allergic reactions (1994) Ann Allergy, 73, pp. 271-272Bosch, M.E., Sánchez, A.J.R., Rojas, F.S., Ojeda, C.B., Analytical methodologies for the determination of cisplatin (2008) J Pharmacol Biomed Anal, 47, pp. 451-459Miller, R.P., Tadagavadi, R.K., Ramesh, G., Reeves, W.B., Mechanisms of cisplatin nephrotoxicity (2010) Toxins, 2, pp. 2490-2518Lippard, S.J., Chemistry and molecular biology of platinum anticancer drugs (1987) Pure Appl Chem, 59, pp. 731-742Makrilia, N., Syrigou, E., Kaklamanos, I., Manolopoulos, L., Saif, M.W., Hypersensitivity reactions associated with platinum antineoplastic agents: A systematic review (2010) Met-Based Drugs, 2010, p. 11Harford, C., Sarkar, B., Studies of induction of metallothionein in Jar (human choriocarcinoma) cells by cis and trans isomers of diamminedichloroplatinum (II) and their hydrolyzed species (1989) Mol Toxicol, 2, pp. 67-7